HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary.

Abstract
Various organizations and agencies have issued recommendations for the management of dyslipidemia. Although many commonalities exist among them, material differences are present as well. The leadership of the National Lipid Association (NLA) convened an Expert Panel to develop a consensus set of recommendations for patient-centered management of dyslipidemia in clinical medicine. The current Executive Summary highlights the major conclusions in Part 1 of the recommendations report of the NLA Expert Panel and includes: (1) background and conceptual framework for formulation of the NLA Expert Panel recommendations; (2) screening and classification of lipoprotein lipid levels in adults; (3) targets for intervention in dyslipidemia management; (4) atherosclerotic cardiovascular disease risk assessment and treatment goals based on risk category; (5) atherogenic cholesterol-non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol-as the primary targets of therapy; and (6) lifestyle and drug therapies intended to reduce morbidity and mortality associated with dyslipidemia.
AuthorsTerry A Jacobson, Matthew K Ito, Kevin C Maki, Carl E Orringer, Harold E Bays, Peter H Jones, James M McKenney, Scott M Grundy, Edward A Gill, Robert A Wild, Don P Wilson, W Virgil Brown
JournalJournal of clinical lipidology (J Clin Lipidol) 2014 Sep-Oct Vol. 8 Issue 5 Pg. 473-88 ISSN: 1933-2874 [Print] United States
PMID25234560 (Publication Type: Journal Article)
CopyrightCopyright © 2014 National Lipid Association. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lipoproteins
Topics
  • Adult
  • Disease Progression
  • Dyslipidemias (drug therapy, epidemiology, metabolism, therapy)
  • Expert Testimony
  • Goals
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors (adverse effects, therapeutic use)
  • Life Style
  • Lipoproteins (metabolism)
  • Risk Assessment
  • Societies, Medical

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: